Received Aug 28, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
I did not have anything more than pain at the injection site with the first dose; This non-serious case was reported by a consumer via call center representative and described the occurrence of injection site pain in a adult female patient who received Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced injection site pain (Verbatim: I did not have anything more than pain at the injection site with the first dose). The outcome of the injection site pain was not reported. It was unknown if the reporter considered the injection site pain to be related to Shingrix. It was unknown if the company considered the injection site pain to be related to Shingrix. Linked case(s) involving the same patient: US2025AMR107892 Additional Information: GSK Receipt Date: 18-AUG-2025 The patient mentioned she did not have anything more than pain at the injection site with the first dose of Shingrix vaccine For tolerance to second dose refer case US2025AMR107892; Sender's Comments: US-GSK-US2025AMR107892:same patient first dose